# US 2021/0277068 A1 · Lipopeptide for potently inhibiting hiv, derivative thereof, pharmaceutical composition thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277068 A1
- Document ID: US20210277068A1
- Status: Published application
- Kind: A1
- Application number: 16/606,525
- Filed: 2017-04-18
- Published: 2021-09-09
- Earliest claimed: 2017-04-18
- Assignees: Shanxi Kangbao Biological Product Co.,Ltd; Institute of Pathogen Biology, Chinese Academy of Medical Sciences
- Applicants: Institute of Pathogen Biology, Chinese Academy of Medical Sciences; Shanxi Kangbao Biological Product Co., Ltd.
- Inventors: Yuxian He; Huihui Chong; Yuanmei Zhu
- Web page: https://patentgrep.com/patent/US20210277068A1

## CPC

- C07K 14/005: from viruses
- C07K 14/162: {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present application relates to a lipopeptide for potently inhibiting HIV, a derivative thereof, or a pharmaceutical composition thereof, and use thereof. The lipopeptide is the following a) or b): a) a lipopeptide formed by linking a polypeptide having an antiviral activity to a lipophilic compound linked to the carboxyl-terminus of the polypeptide; or b) a lipopeptide formed by linking a polypeptide having an antiviral activity to a terminal protecting group and a lipophilic compound linked to the carboxyl-terminus of the polypeptide, wherein the terminal protecting group is an amino-terminal protecting group and/or a carboxyl-terminal protecting group, the polypeptide has a sequence of 28 amino acid residues, corresponding to amino acids at positions of 127-154 of the sequence of gp41 from HIV-1 strain HXB2. The anti-HIV activity of the lipopeptide of the present invention is higher than that of T-20 by several thousands of times or even tens of thousands of times, and is also significantly higher than that of the anti-HIV lipopeptides such as C34-Chol, LP-19 and the like.

## Claims

### Claim 1

A lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, characterized in that the lipopeptide is the following a) or b):
a) a lipopeptide formed by linking a polypeptide having an antiviral activity to a lipophilic compound linked to the carboxyl-terminus of the polypeptide;
b) a lipopeptide formed by linking a polypeptide having an antiviral activity to a terminal protecting group and a lipophilic compound linked to the carboxyl-terminus of the polypeptide, wherein the terminal protecting group is an amino terminal protecting group and/or a carboxyl terminal protecting group;
in the a) and b), the polypeptide is any one of P1 to P5:
the P1 has a sequence as shown in the following Formula I,
X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25X26X27X28 Formula I
in the Formula I,
X1 to X28 are each an amino acid residue, X1 is W, L or Y, the X2 is E or T, X3 is Q, A or S, X4 is K, N or L, X5 is I or L, X6 is E, D, K, R or A, X7 is E, D, K, R or A, X8 is L or I, X9 is L or I, X10 is K, R, E, D or A, X11 is K, R, E, D or A, X12 is A or S, X13 is E, D, K, R or A, X14 is E, D, K, R or A, X15 is Q, X16 Q, X17 is K, R, E, D or A, X18 is K, R, E, D or A, X19 is N, X20 is E or D, and X21 is E, D, K, R or A, X22 is E, D, K, R or A, X23 is L or I, X24 is K, R, E, D or A, X25 is K, R, E, D or A, X26 is L or I, X27 is E Or D, X28 is K or R;
the P2 is a polypeptide obtained by deleting 1 to 4 amino acid residues at the amino-terminus of the P1;
the P3 is a polypeptide obtained by deleting 1 to 3 amino acid residues at the carboxyl-terminus of the P1;
the P4 is a polypeptide obtained by adding a cysteine residue to the carboxyl-terminus of the P1;
the P5 has a sequence as shown in the following Formula II,
X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25, Formula II
in the Formula II, the definitions of X5 to X25 are same as those in the Formula I;
and the polypeptide having an antiviral activity against any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim 2 (depends on 1)

The lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 1, characterized in that
the lipopeptide has an antiviral activity higher than that of LP-19 and/or T-20 and/or C34-Chol;
the derivative of the lipopeptide is obtained by replacing one or more of amino acid resides of the polypeptide of the lipopeptide with L-form or D-form amino acids, artificially modified amino acids and/or rare amino acids present in nature, and has a bioavailability, stability, and/or antiviral activity higher than that of the polypeptide.

### Claim 3 (depends on 1)

The lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 1, characterized in that
the P1 has a sequence as shown in the following sequence:
X1X2X3X4IEELX9KKX12EEQQKKNEEELKKLEK;
the P2 is P2-1, P2-2, P2-3 or P2-4, wherein
the P2-1 has a sequence as shown in the following sequence:
X2X3X4IEELX9KKX12EEQQKKNEEELKKLEK;
the P2-2 has a sequence as shown in the following sequence:
X3X4IEELX9KKX12EEQQKKNEEELKKLEK;
the P2-3 has a sequence as shown in the following sequence:
X4IEELX9KKX12EEQQKKNEEELKKLEK;
the P2-4 has a sequence as shown in the following sequence:
IEELX9KKX12EEQQKKNEEELKKLEK;
the P3 has a sequence as shown in the following sequence:
X1X2X3X4IEELX9KKX12EEQQKKNEEELKK;
the P4 has a sequence as shown in the following sequence:
X1X2X3X4IEELX9KKX12EEQQKKNEEELKKLEKC;
in the P1, P2-1, P2-2, P2-3, P2-4, P3 and P4, the definitions of X1, X2, X3, X4, X9 and X12 are same as those in the Formula I.

### Claim 4 (depends on 3)

The lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 3, characterized in that
the P1 is P-80/84/85/52, P-87/51 or P50, wherein the P-80/84/85/52 is a polypeptide represented by the sequence of SEQ ID NO: 1 in the sequence listing, the P-87/51 is a polypeptide represented by the sequence of SEQ ID NO: 2 in the sequence listing, and the P50 is a polypeptide represented by the sequence of SEQ ID NO: 3 in the sequence listing;
the P2-1 is P-88/62, wherein the P-88/62 is a polypeptide represented by the sequence of SEQ ID NO: 4 in the sequence listing;
the P2-2 is P63 or P60, wherein the P63 is a polypeptide represented by the sequence of SEQ ID NO: 5 in the sequence listing, and the P60 is a polypeptide represented by the sequence of SEQ ID NO: 6 in the sequence listing;
the P2-3 is P-89/64, wherein the P-89/64 is a polypeptide represented by the sequence of SEQ ID NO: 7 in the sequence listing;
the P2-4 is P-90/65 or P61, wherein the P-90/65 is a polypeptide represented by the sequence of SEQ ID NO: 8 in the sequence listing; and the P61 a polypeptide represented by the sequence of SEQ ID NO: 9 in the sequence listing;
the P3 is P-91/55, wherein the P-91/55 is a polypeptide represented by the sequence of SEQ ID NO: 10 in the sequence listing; and
the P4 is a P83 or P86, wherein the P83 is a polypeptide represented by the sequence of SEQ ID NO: 11 in the sequence listing, and the P86 is a polypeptide represented by the sequence of SEQ ID NO: 12 in the sequence listing.

### Claim 5 (depends on 1)

The lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 1, characterized in that the lipophilic compound is a fatty acid containing 8 to 20 carbon atoms, cholesterol, dihydrosphingosine or vitamin E.

### Claim 6 (depends on 5)

The lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 5, characterized in that the fatty acid containing 8 to 20 carbon atoms is stearic acid or palmitic acid.

### Claim 7 (depends on 6)

The lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 6, characterized in that
the lipopeptide is any one of the following 12 lipopeptides LP-80/84/85/52, LP-90/65, LP-87/51, LP-88/62, LP-50, LP-83, LP-91/55, LP-86, LP-63, LP-89/64, LP-60 and LP-61;
the LP-80/84/85/52 is LP-80/84/85/52a or LP-80/84/85/52b, wherein the LP-80/84/85/52a is formed by linking a polypeptide named as P-80/84/85/52 to a lipophilic compound linked to the carboxyl-terminus of the P-80/84/85/52; the LP-80/84/85/52b is formed by linking the LP-80/84/85/52a to the terminal-protecting group; in the LP-80/84/85/52a and LP-80/84/85/52b, the P-80/84/85/52 is the polypeptide represented by the sequence of SEQ ID NO: 1 in the sequence listing, and the lipophilic compound is stearic acid, dihydrosphingosine, or vitamin E;
the LP-90/65 is LP-90/65a or LP-90/65b, wherein the LP-90/65a is formed by linking a polypeptide named as P-90/65 to a lipophilic compound linked to the carboxyl-terminus of the P-90/65; the LP-90/65b is formed by linking the LP-90/65a to the terminal protecting group; in the LP-90/65a and LP-90/65b, the P-90/65 is a polypeptide represented by the sequence of SEQ ID NO: 8 in the sequence listing, and the lipophilic compound is stearic acid or palmitic acid;
the LP-87/51 is LP-87/51a or LP-87/51b, wherein the LP-87/51a is formed by linking a polypeptide named as P-87/51 to a lipophilic compound linked to the carboxyl-terminus of the P-87/51; the LP-87/51b is formed by linking the LP-87/51a to the terminal protecting group; in the LP-87/51a and LP-87/51b, the P-87/51 is a polypeptide represented by the sequence of SEQ ID NO: 2 in the sequence listing, and the lipophilic compound is dihydrosphingosine or palmitic acid;
the LP-88/62 is LP-88/62a or LP-88/62b, wherein the LP-88/62a is formed by linking a polypeptide named as P-88/62 to a lipophilic compound linked to the carboxyl-terminus of the P-88/62; the LP-88/62b is formed by linking the LP-88/62a to the terminal protecting group; in the LP-88/62a and LP-88/62b, the P-88/62 is a polypeptide represented by the sequence of SEQ ID NO: 4, and the lipophilic compound is stearic acid or palmitic acid;
the LP-50 is LP-50a or LP-50b, wherein the LP-50a is formed by linking a polypeptide named as P50 to palmitic acid linked to the carboxyl-terminus of the P50; the LP-50b is formed by linking the LP-50a to the terminal protecting group; in the LP-50a and LP-50b, the P50 is a polypeptide represented by the sequence of SEQ ID NO: 3 in the sequence listing;
the LP-83 is LP-83a or LP-83b, wherein the LP-83a is formed by linking a polypeptide named as P83 to cholesterol linked to the carboxyl-terminus of the P83; the LP-83b is formed by linking the LP-83a to the terminal protecting group; in the LP-83a and LP-83b, the P83 is a polypeptide represented by the sequence of SEQ ID NO: 11 in the sequence listing;
the LP-91/55 is LP-91/55a or LP-91/55b, wherein the LP-91/55a is formed by linking a polypeptide named as P-91/55 to a lipophilic compound linked to the carboxyl-terminus of the P-91/55; the LP-91/55b is formed by linking the LP-91/55a to the terminal protecting group; in the LP-91/55a and LP-91/55b, the P-91/55 is a polypeptide represented by the sequence of SEQ ID NO: 10, and the lipophilic compound is stearic acid or palmitic acid;
the LP-86 is LP-86a or LP-86b, wherein the LP-86a is formed by linking a polypeptide named as P86 to cholesterol linked to the carboxyl-terminus of the P86; the LP-86b is formed by linking the LP-86a to the terminal protecting group; in the LP-86a and LP-86b, the P86 is a polypeptide represented by the sequence of SEQ ID NO: 12 in the sequence listing;
the LP-63 is LP-63a or LP-63b, wherein the LP-63a is formed by linking a polypeptide named as P63 to palmitic acid linked to the carboxyl-terminus of the P63; the LP-63b is formed by linking the LP-63a to the terminal protecting group; in the LP-63a and LP-63b, the P63 is a polypeptide represented by the sequence of SEQ ID NO: 5 in the sequence listing;
the LP-89/64 is LP-89/64a or LP-89/64b, wherein the LP-89/64a is formed by linking a polypeptide named as P-89/64 to a lipophilic compound linked to the carboxyl-terminus of the P-89/64; the LP-89/64b is formed by linking the LP-89/64a to the terminal protecting group; in the LP-89/64a and LP-89/64b, the P-89/64 is a polypeptide represented by the sequence of SEQ ID NO: 7 in the sequence listing, and the lipophilic compound is stearic acid or palmitic acid;
the LP-60 is LP-60a or LP-60b, wherein the LP-60a is formed by linking a polypeptide named as P60 to palmitic acid linked to the carboxyl-terminus of the P60; the LP-60b is formed by linking the LP-60a to the terminal protecting group; in the LP-60a and LP-60b, the P60 is a polypeptide represented by the sequence of SEQ ID NO: 6 in the sequence listing; and
the LP-61 is LP-61a or LP-61b, wherein the LP-61a is formed by linking a polypeptide named as P61 to palmitic acid linked to the carboxyl-terminus of the P61; the LP-61b is formed by linking the LP-61a to the terminal protecting group; in the LP-61a and LP-61b, the P61 is a polypeptide represented by the sequence of SEQ ID NO: 9 in the sequence listing.

### Claim 8 (depends on 1)

A polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, characterized in that the polypeptide is a polypeptide defined in claim 1.

### Claim 9 (depends on 8)

The polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 8, characterized in that the derivative of the polypeptide is at least one selected from the group consisting of the following 1) to 5):
1) a derivative obtained by linking a N-terminal protecting group to the amino-terminus of the polypeptide and/or by linking a C-terminal protecting group to the carboxyl-terminus of the polypeptide;
2) a derivative obtained by linking an oligopeptide or a lipophilic compound to the carboxyl-terminus of the polypeptide;
3) a derivative obtained by linking an oligopeptide or a lipophilic compound to the amino-terminus of the polypeptide;
4) a derivative obtained by linking an oligopeptide or a lipophilic compound to the both carboxyl-terminus and amino-terminus of the polypeptide; and
5) a derivative obtained by modifying the polypeptide with a protein, a polyethylene glycol or a maleimide.

### Claim 10 (depends on 1)

A multimer of PM1, wherein
the PM1 is a multimer formed by the lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 1.

### Claim 11 (depends on 1)

A composition comprising C1) and C2), wherein,
the C1) is C11), wherein the C11) is the lipopeptide, a derivative, or a pharmaceutically acceptable salt thereof according to claim 1;
the C2) is a pharmaceutically acceptable carrier or adjuvant;
the composition has at least one function of the following functions F1)-F5):
F1) having activity against virus;
F2) treating and/or preventing and/or adjunctively treating a disease caused by a virus infection;
F3) inhibiting fusion of virus and cell;
F4) inhibiting entry of virus into cell; and
F5) inhibiting replication of virus;
in the F1)-F5), the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim at position 12

12-14. (canceled)

### Claim 15 (depends on 1)

A method of treating or/and preventing an infection caused by a virus in an animal, comprising administering to a subject animal the C11) to inhibit viral infection in the animal, wherein
the C11) is the lipopeptide, a derivative, or a pharmaceutically acceptable salt thereof according to claim 1;
the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim 16 (depends on 8)

A multimer of PM2, wherein
the PM2 is a multimer formed by the lipopeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof according to claim 8.

### Claim 17 (depends on 8)

A composition comprising C1) and C2), wherein,
the C1) is C12), wherein the C12) is the polypeptide, a derivative thereof, or a pharmaceutically acceptable salt thereof according to claim 8;
the C2) is a pharmaceutically acceptable carrier or adjuvant;
the composition has at least one function of the following functions F1)-F5):
F1) having activity against virus;
F2) treating and/or preventing and/or adjunctively treating a disease caused by a virus infection;
F3) inhibiting fusion of virus and cell;
F4) inhibiting entry of virus into cell; and
F5) inhibiting replication of virus;
in the F1)-F5), the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim 18 (depends on 10)

A composition comprising C1) and C2), wherein,
the C1) is C13), wherein the C13) is the multimer according to claim 10;
the C2) is a pharmaceutically acceptable carrier or adjuvant;
the composition has at least one function of the following functions F1)-F5):
F1) having activity against virus;
F2) treating and/or preventing and/or adjunctively treating a disease caused by a virus infection;
F3) inhibiting fusion of virus and cell;
F4) inhibiting entry of virus into cell; and
F5) inhibiting replication of virus;
in the F1)-F5), the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim 19 (depends on 8)

A method of treating or/and preventing an infection caused by a virus in an animal, comprising administering to a subject animal the C12) to inhibit viral infection in the animal, wherein
the C12) is the polypeptide, a derivative thereof, or a pharmaceutically acceptable salt thereof according to claim 8;
the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim 20 (depends on 10)

A method of treating or/and preventing an infection caused by a virus in an animal, comprising administering to a subject animal the C13) to inhibit viral infection in the animal, wherein
the C13) is the multimer according to claim 10;
the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.

### Claim 21 (depends on 11)

A method of treating or/and preventing an infection caused by a virus in an animal, comprising administering to a subject animal the C14) to inhibit viral infection in the animal, wherein
the C14) is the composition according to claim 11;
the virus is any one virus selected from the group consisting of the following v1-v7:
v1: HIV-1, HIV-2 and SIV;
v2: HIV-1 and HIV-2;
v3: HIV-1 and SIV;
v4: HIV-2 and SIV;
v5: HIV-1;
v6: HIV-2; and
v7: SIV.
